Anatara Lifesciences Limited

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. 

 

 
    

News

Anatara Lifesciences Limited (ASX:ANR) Webinar on the Company's Stage 1 Irritable Bowel Syndrome

🕔10/18/2023 12:51:31 PM 2363

Anatara Lifesciences (ASX:ANR) is pleased to invite shareholders, investors and interested parties to an online Webinar on the Company's Stage 1 Irritable Bowel Syndrome (IBS) clinical trial results, hosted by Chair, Dr. David Brookes.

Read Full Article

Anatara Lifesciences Limited (ASX:ANR) Annual Report to Shareholders

🕔10/15/2021 5:44:13 PM 4120

2021 has been a significant year for Anatara Lifesciences Limited (ASX:ANR), as we made steps towards progressing our human health products towards clinical trials, successfully completed animal health studies and progressed licensing discussions.

Read Full Article

Anatara Lifesciences Limited (ASX:ANR) Meet the CEO Investor Webinar

🕔9/7/2021 10:44:18 AM 3827

Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal health in humans and animals, invites shareholders to attend a virtual group briefing with Chief Executive Officer, Steven Lydeamore, on Thursday 9 September 2021 at 11:00am AEST.

Read Full Article

Anatara Lifesciences Limited (ASX:ANR) Investor Presentation

🕔9/6/2021 9:36:59 AM 3953

Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals, is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today to investors.

Read Full Article

Anatara Lifesciences Limited (ASX:ANR) Launches IBS-D Clinical Trial Recruitment Website

🕔8/20/2021 8:13:43 AM 4896

Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to announce the launch of its IBS-D Clinical Trial recruitment website.

Read Full Article

Anatara Lifesciences Limited (ASX:ANR) Successful Piglet Study

🕔8/6/2021 9:02:29 AM 4361

Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to announce the successful completion of a challenge study in weaner piglets with its recently developed bromelain-based formulation (BONIFF).

Read Full Article

Anatara Lifesciences Limited (ASX:ANR) Monthly Activities Report

🕔7/28/2021 10:29:48 AM 4011

Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 30 June 2021 (Q4 FY21), along with the Company's Appendix 4C cash flow report.

Read Full Article

Anatara Lifesciences Limited (ASX:ANR) Chair Transition

🕔7/26/2021 10:14:43 AM 3801

Anatara Lifesciences (ASX:ANR), a developer of evidence-based solutions for gastrointestinal diseases in humans and animals, is pleased to announce the transition of Dr David Brookes from Non-Executive Director to Chairman.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Progressing Towards First Human Clinical Studies

🕔5/31/2021 8:41:43 AM 3392

Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals is pleased to provide this update on clinical trial activities.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Q3 FY21 Activities Report

🕔4/27/2021 8:34:50 AM 3630

Anatara Lifesciences (ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Company's Appendix 4C cash flow report.

Read Full Article
###

107,529 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 325) (Last 30 Days: 1489) (Since Published: 107529) 

Company Data

    Headquarters
  • Level 3, 62 Lygon Street
    Carlton South, VIC, 3053
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports

More News Results

  • 2024/10/08: GaRP-IBS Irritable Bowel Syndrome Clinical Trial Update*
  • 2024/10/02: Appendix 4G and Corporate Governance Statement*
  • 2024/10/02: Annual Report to shareholders*
  • 2024/10/02: Notice of Annual General Meeting/Proxy Form*
  • 2024/10/01: European Patent Granted for GaRP Product Addendum*
  • 2024/09/20: Anatara's GaRP granted EU patent*
  • 2024/09/10: Anatara Annual General Meeting & Director Nominations*
  • 2024/08/30: GaRP Irritable Bowel Syndrome Clinical Trial Update*
  • 2024/08/29: $626,000 received in R&D Tax Incentive for FY24*
  • 2024/08/22: Appendix 4E & Financial Report 30 June 2024*
*refer to company website

Presentations

Download Presentation

Research Report

Download Presentation

Quarterly Report

Download Presentation

Social Media